NEWSROOM

Immune Therapeutics

Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company

The Planned Acquisition Would Enhance the Management Team, Provide Capital and Bring Additional Oncology Assets to Immune’s Pipeline   ORLANDO, Fla., December 16th, 2019  -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a privately held development-stage oncology therapeutics company, today announced that Immune will acquire Aletheia in an all-stock transaction.  Pursuant to completion of a definitive agreement,...

read more

Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change

    ORLANDO, Fla., October 28, 2019 — – Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies for the treatment of cancer using an immune therapy  and a systems biology approach today announced that its Board of Directors and a majority of its shareholders have approved a reverse stock split of the Company’s issued and outstanding common shares at a ratio of 1,000 to 1 and a...

read more

Immune Therapeutics, Inc. Announces Advisory Board Appointments

  ORLANDO, Fla., October 22, 2019 -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that Dr. Robert Buckheit, Jr. will join the Scientific Advisory Board (“SAB”) of Immune Therapeutics. ”Immune Therapeutics is fortunate to have an individual as capable as Dr. Buckheit helping...

read more

Immune Therapeutics Inc. Management Advises All Shareholders to Vote Their Proxy Card Today

                Immune Therapeutics Inc. Management Urges Shareholders to Vote Yes and Support the Company's Three Proposals   ORLANDO, FL – September 26, 2019 – – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today urges shareholder to vote yes for all three proposals. Immune...

read more

Immune Therapeutics Inc Advises All Shareholders to Vote Their Proxy Card Today

      Immune Therapeutics Inc Urges Shareholders to Vote Yes and Support the Company's Three Proposals   ORLANDO, FL – September 17, 2019) -- – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today urges shareholder to vote yes for all three proposals. Over the last week...

read more

Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors

          ORLANDO, Fla., September 23, 2019 — –Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis is pleased to announce the appointment of Michael K. Handley as the new Chief Executive Officer of Immune Therapeutics’ and Member of the Board...

read more

Immune Therapeutics Revises and Resends Proxy Statement

             ORLANDO, FL – September 10, 2019 -- – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, has filed a Revised Definitive Proxy Statement (the “Revised Proxy Statement”) due to the discovery that, as a result of an error outside of the Company’s control, shareholders...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »